Bruce Chabner, chief of hematology and oncology at Massachusetts General Hospital, is the newest member of the scientific and clinical advisory committee at Adherex Technologies.

Chabner, an MD, also has experience in designing clinical trials and is a professor of medicine at Harvard Medical School.

“He is known world-wide as one of the most experienced developers of cancer drugs and his expertise in cancer as well as clinical trial design will be extremely valuable for Adherex as it develops its portfolio of novel drug candidates,” said Donald Kufe, MD, chairman of the committee and an Adherex board member.